A Double-blind, Randomized, Placebo Controlled Single Site Study to Evaluate the Effects of Evolocumab (AMG 145) Treatment Alone and in Combination with Atorvastatin on Lipoprotein Kinetics

Project Details

StatusFinished
Effective start/end date1/07/1430/06/17

Funding

  • Amgen Australia Pty Ltd: AUD520,974.00
  • Amgen Australia Pty Ltd: AUD632,376.00
  • Amgen Australia Pty Ltd: AUD278,893.00
  • Amgen Australia Pty Ltd: AUD157,686.00